US Patent

US12102637 — Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

Formulation · Assigned to Neurocrine Biosciences Inc · Expires 2038-08-20 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical formulations containing a gonadotropin-releasing hormone antagonist for treating endometriosis, uterine fibroids, polycystic ovary syndrome, or adenomyosis.

USPTO Abstract

The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number
US12102637
Jurisdiction
US
Classification
Formulation
Expires
2038-08-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.